Octreotide: effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial

What Was Tested

The paper reports a study of Octreotide in the context of hyperparathyroidism, published as a randomized controlled trial.

In a prospective, randomized, controlled, triple blinded clinical trial in patients with primary or secondary hyperparathyroidism, the researchers evaluated the response of biochemical parameters relevant in hyperparathyroidism to the somatostatin analog octreotide.

Who Took Part

PubMed indexes the participants as teenagers, adults, middle-aged adults and older adults, both men and women.

Subsequent to operation, which was performed on all patients, somatostatin-receptor autoradiography of parathyroid tissue was performed.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Some participants received a placebo instead of Octreotide, giving a reference point.

What Was Measured

In a prospective, randomized, controlled, triple blinded clinical trial in patients with primary or secondary hyperparathyroidism, the researchers evaluated the response of biochemical parameters relevant in hyperparathyroidism to the somatostatin analog octreotide.

The subject headings attached to it are Calcium, Hyperparathyroidism, Octreotide, Parathyroid Hormone and Receptors, Somatostatin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Octreotide in people with hyperparathyroidism.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Surgery), a journal based in United States.

More context: the Octreotide compound page, Hyperparathyroidism research.